Truist Financial Increases Eli Lilly and Company (NYSE:LLY) Price Target to $1,038.00

Eli Lilly and Company (NYSE:LLY) had its price target increased by research analysts at Truist Financial from $1,029.00 to $1,038.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 25.45% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Wells Fargo & Company cut their price objective on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Finally, Sanford C. Bernstein began coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Trading Up 2.1 %

NYSE:LLY opened at $827.41 on Monday. Eli Lilly and Company has a 12 month low of $682.53 and a 12 month high of $972.53. The business’s 50-day moving average is $784.69 and its two-hundred day moving average is $843.49. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market capitalization of $785.48 billion, a PE ratio of 89.45, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42.

Eli Lilly and Company declared that its board has initiated a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.13% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Cutter & CO Brokerage Inc. boosted its stake in Eli Lilly and Company by 28.1% in the fourth quarter. Cutter & CO Brokerage Inc. now owns 8,785 shares of the company’s stock valued at $6,782,000 after acquiring an additional 1,925 shares during the last quarter. GraniteShares Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $2,673,000. Lake Street Advisors Group LLC boosted its position in shares of Eli Lilly and Company by 2.0% in the 4th quarter. Lake Street Advisors Group LLC now owns 11,019 shares of the company’s stock worth $8,507,000 after purchasing an additional 211 shares during the last quarter. Kirtland Hills Capital Management LLC grew its stake in shares of Eli Lilly and Company by 25.4% during the fourth quarter. Kirtland Hills Capital Management LLC now owns 306 shares of the company’s stock worth $237,000 after purchasing an additional 62 shares during the period. Finally, Daner Wealth Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $402,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.